SCHEMBL26675963

SCHEMBL26675963

COc1ccc2c(c1)c1c(n2COCC[Si](C)(C)C)C2C=CCN(CC1)C2

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTR6 P50406 4/20 0.35
▸ HRH1 P35367 3/20 0.35
▸ SLC6A4 P31645 1/20 0.35
▸ MAOA P21397 2/20 0.35
▸ MAOB P27338 2/20 0.35
▸ NPC1 O15118 1/20 0.34
▸ AKR1B10 O60218 2/20 0.33
▸ AKR1B1 P15121 2/20 0.33
▸ AKR1A1 P14550 1/20 0.33
▸ GRIK1 P39086 1/20 0.32
▸ GRIK2 Q13002 1/20 0.32
▸ DRD2 P14416 1/20 0.31
▸ DRD1 P21728 1/20 0.31
▸ DRD5 P21918 1/20 0.31
▸ DRD3 P35462 1/20 0.31
▸ PTGDR2 Q9Y5Y4 1/20 0.31
▸ KDM4E B2RXH2 1/20 0.31
▸ HSD17B10 Q99714 1/20 0.31
▸ ESR1 P03372 2/20 0.30
▸ HTR5A P47898 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29736069 1.00 HTR6 (0.35) HTR6HRH1SLC6A4MAOAMAOB
SCHEMBL26675974 0.87 NPC1 (0.39) HTR6HRH1SLC6A4NPC1
SCHEMBL26675933 0.81 SLC6A4 (0.36) HTR6HRH1SLC6A4MAOAMAOB
SCHEMBL26837609 0.69 MAOA (0.40) MAOANPC1KDM4EHSD17B10
SCHEMBL26675985 0.67 NPC1 (0.40) HRH1NPC1
SCHEMBL26675959 0.65 MAOA (0.45) HTR6MAOAMAOBNPC1ESR1
SCHEMBL28840658 0.64 GRIK2 (0.39) MAOAMAOBNPC1GRIK1GRIK2
SCHEMBL25297650 0.61 PTGER4 (0.40) NPC1GRIK1GRIK2KDM4EHSD17B10
SCHEMBL25254239 0.60 ADRB2 (0.43) HTR6MAOBNPC1GRIK1GRIK2
SCHEMBL28841058 0.60 HTR2C (0.51) HTR6KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4288048-A1 OXA-IBOGAINE INSPIRED ANALOGUES FOR TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS The Trustees Of Columbia University In The City Of New York (US) 2023-12-13 — — EP disclosed
US-20230382919-A1 OXA- IBOGAINE INSPIRED ANALOGUES FOR TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2023-11-30 — — US disclosed
US-20230382919-A1 OXA- IBOGAINE INSPIRED ANALOGUES FOR TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2023-11-30 — — US disclosed
US-20230382919-A1 OXA- IBOGAINE INSPIRED ANALOGUES FOR TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2023-11-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230382919-A1 OXA- IBOGAINE INSPIRED ANALOGUES FOR TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS GRIA4, GRIA3, GRIN3A HTR6 179/4885HRH1 125/4885SLC6A4 230/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback